FIGO 2018分期联合MRI与PET对局部区域晚期宫颈癌的预后意义及治疗选择启示
本研究基于1996至2014年间接受根治性放疗的744例局部区域晚期宫颈癌患者,依据病理、MRI和PET结果按FIGO 2018分期重新分类,分析5年生存。结果显示多数患者发生分期迁移,各FIGO 2018分期5年生存异质,而按原发肿瘤体积和淋巴结状态合并的5个等预后组预后逐步恶化(p < 0.002)。
要点
- 744例局部区域晚期宫颈癌患者按FIGO 2018分期重新分类后,多数发生分期迁移。
- 按FIGO 2018分期各期5年生存异质,而5个等预后组预后逐步恶化(p < 0.002)。
- 局部区域晚期宫颈癌预后取决于原发肿瘤特征、局部扩散类型与淋巴结病变的相互作用。
核心结论
- 局部区域晚期宫颈癌的预后取决于原发肿瘤特征、局部扩散类型与淋巴结病变之间的相互作用。
- 作者认为,按等预后组开展生存与失败模式的前瞻性研究有助于确定最合适的治疗方式、估计生存并更好地为临床试验筛选患者。
研究设计与样本
- 研究纳入1996年至2014年间接受根治性放疗的局部区域晚期宫颈癌患者。
- 基线临床病理与随访信息取自经伦理批准的研究机构前瞻性数据库。
- 依据组织病理学、MRI(评估肿瘤体积与局部间室扩散)和PET结果(评估淋巴结扩散)按FIGO 2018分期分类。
- 采用Kaplan-Meier法估计5年生存率,并在使用公认预后因素进行生存分析后识别等预后类别并合并为5个等预后组。
主要发现
- 共纳入744例局部区域晚期宫颈癌患者,中位随访5.1年(IQR 2.6-8.4年)。
- 多数患者发生分期迁移,按FIGO 2018分期各期5年生存呈现异质性。
- 5个观察到的等预后组预后逐步恶化(p < 0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The FIGO 2018 staging of cervix cancer recognizes a total of 11 categories of loco-regionally advanced cervix cancer (LRACC). Whilst incorporating imaging is an improvement over clinical staging (FIGO 2009), this had led to more categories of disease which are not prognostically discrete groups. We aimed to analyze survival according to 2018 FIGO stages of cervix cancer and identify isoprognostic groups of patients based on primary tumor volume and nodal status. METHODS: Patients referred for radiotherapy with curative intent between 1996 and 2014 were eligible. Baseline clinico-pathological and follow up information was retrieved from an ethics-approved institutional prospective database. Patients were classified according to FIGO 2018 staging based on histo-pathology, MRI (tumor volume and local compartmental spread assessment) and PET results (nodal spread). Kaplan-Meier method was used to estimate survival at five years. Following survival analysis using recognized prognostic factors, isoprognostic categories were identified and merged to form 5 isoprognostic groups. RESULTS: Seven hundred and forty-four LRACC patients were included. The median (IQR) follow-up was 5.1 (2.6-8.4) yrs. Stage migration occurred in most patients, showing heterogeneous 5 years survival according to 2018 FIGO stages. In contrast progressively worsening prognosis could be demonstrated in the 5 observed isoprognostic clusters (p < 0.002). CONCLUSION/IMPLICATIONS: Prognosis in LRACC depends on the interplay between primary tumor characteristics, type of local spread and nodal disease. A prospective study of survival and patterns of failure according to isoprognostic clusters would be useful to determine the most appropriate treatment modality and estimate survival as well as better patient selection for clinical trials.
引用
- Lin MY, Mileshkin L, McNally O, et al. Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection. Gynecol Oncol. 2022. PMID: 36521354. doi:10.1016/j.ygyno.2022.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。